News

Boehringer Ingelheim is celebrating the approval of its first oncology drug after regulators in the USA gave the green light to Gilotrif for late-stage non-small cell lung cancer.

GlaxoSmithKline says it has found no evidence of its employees in China paying bribes to doctors and hospitals, despite claims made by the country’s Public Security Bureau.

Canada’s protection of intellectual property (IP) in the pharmaceutical industry falls short of international standards and could hinder its ability to negotiate international trade deals now under discussion, a new report warns.

Pfizer is expanding two of its manufacturing plants in Ireland, investing $100 million into the Grange Castle facility in Dublin and $30 million at its Ringaskiddy site in Cork.

Thirty-six companies participated in the new PharmaTimes Sales Awards, which encompass PharmaTimes Sales Representative of the Year and PharmaTimes Business Manager of the Year competitions, with the winners announced at a presentation ceremony in London on 11 July.  

Roche has terminated development of aleglitazar due to safety concerns about the late-stage diabetes treatment.

Cost regulators for NHS Scotland have given children with Crohn’s disease routine access to AbbVie’s Humira, marking the first of the UK nations to accept the drug’s use in this setting.

Theorem Clinical Research, the US-based provider of clinical research and development services, has boosted its resources in regulatory consulting and medical devices/diagnostics through a strategic partnership with Emergo Group.

Vifor Pharma has published findings from a major study which shows that its intravenous treatment Ferinject significantly prolongs the time until other anaemia treatment is needed.

The University of Manchester and the city’s specialist cancer centre, the Christie NHS Foundation Trust, are putting £30 million into a recruitment drive for academic researchers and their teams to support the Manchester Cancer Research Centre (MCRC).

ALK-Abello’s experimental house dust mite allergy pill remains on track for a 2014 filing, after a second Phase III trial assessing its safety and efficacy achieved its targets.

The European Union (EU) has been urged to act swiftly to deal with the “dreadful” situation faced by millions of people in terms of access to medicines, so that “a public health disaster” can be avoided.

Some employees at GlaxoSmithKline who are being investigated in China for suspected bribery and tax-related violations have already confessed to the offences, according to the state-owned Xinhua news agency.

“Bold, clinically-led changes” to how NHS services are delivered must be instilled over the next couple of years to address a funding gap that could hit a whopping £30 billion over the next few years, NHS England has warned.

The National Institute for Health and Care Excellence (NICE) has issued new draft guidance not recommending Celgene’s Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes (MDS), but has also opened a public consultation on this preliminary decision.